Albert Kildani - ACADIA Pharmaceuticals Senior Communications
| ACAD Stock | USD 16.54 0.17 1.04% |
Executive
Albert Kildani is Senior Communications of ACADIA Pharmaceuticals
| Address | 12830 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 558 2871 |
| Web | https://www.acadia.com |
ACADIA Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0872 % which means that it generated a profit of $0.0872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2736 %, meaning that it created $0.2736 on every $100 dollars invested by stockholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.4 M, whereas Net Tangible Assets are forecasted to decline to about 403.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Hassman | Scpharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Nicole Esq | HCW Biologics | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| RPh Young | Seres Therapeutics | 57 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| MD FAAP | Lumos Pharma | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| JD Esq | Seres Therapeutics | 69 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Eddie MBA | Lumos Pharma | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Caroline Holda | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0872 |
ACADIA Pharmaceuticals Leadership Team
Elected by the shareholders, the ACADIA Pharmaceuticals' board of directors comprises two types of representatives: ACADIA Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACADIA. The board's role is to monitor ACADIA Pharmaceuticals' management team and ensure that shareholders' interests are well served. ACADIA Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ACADIA Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Parag PharmD, Senior Franchise | ||
| Elizabeth Thompson, Executive Development | ||
| Bob Mischler, Senior Strategy | ||
| Albert Kildani, Senior Communications | ||
| Douglas MD, Executive Development | ||
| Stephen JD, CEO President | ||
| James Kihara, Chief VP | ||
| Jennifer JD, Chief VP | ||
| Kimberly Manhard, Senior Execution | ||
| Catherine Adams, CEO Director | ||
| Rob Ackles, Senior Officer | ||
| Julie Fisher, Senior Strategy | ||
| MSPH MD, President | ||
| Holly Valdiviez, Senior Sales | ||
| Brendan Teehan, COO VP | ||
| Erika Zavod, Planning, Strategy | ||
| Austin Kim, Executive Vice President General Counsel, Secretary | ||
| Sanjeev MD, Senior Development | ||
| Mark Schneyer, Executive CFO | ||
| Kevin Oliver, Senior Officer | ||
| Stephanie Kim, Senior Affairs | ||
| Mark Johnson, Vice President Investor Relations | ||
| Benir Ruano, Operations Development | ||
| MPH MD, Global SVP |
ACADIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ACADIA Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 2.24 B | ||||
| Shares Outstanding | 166.39 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 97.10 % | ||||
| Number Of Shares Shorted | 9.53 M | ||||
| Price To Earning | (13.77) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.